VESPER: Phase III Trial of Perioperative Chemotherapy With Dose-Dense MVAC vs Gemcitabine + Cisplatin in Patients With Muscle-Invasive Bladder Cancer

September 16-21, 2021; Virtual
Among patients with muscle-invasive bladder cancer, dose-dense MVAC significantly improved the 3-year rate of PFS and time to progression vs gemcitabine plus cisplatin in the neoadjuvant setting.
Format: Microsoft PowerPoint (.ppt)
File Size: 199 KB
Released: September 27, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Exelixis, Inc.
Ipsen Biopharmaceuticals, Inc.

Related Content

Clinical Care Options (CCO): Expert analysis from Drs. Daniel Petrylak and Toni Choueiri on key data in genitourinary cancers from ASCO GU 2022

Toni K. Choueiri, MD Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 18, 2022 Expired: April 17, 2023

Expert slides on key data from ASCO GU 2022 on prostate cancer, urothelial cancers, renal cell carcinoma, and more, from Clinical Care Options (CCO)

Released: February 28, 2022

Clinical Care Options (CCO): Joshua Sabari, MD, provides insights into the emerging targeted therapies for patients with NRG1-positive solid tumors

Joshua Sabari, MD Released: February 28, 2022

Expert commentary previewing key studies at 2022 ASCO Genitourinary Cancers Symposium annual meeting, from Clinical Care Options (CCO)

Toni K. Choueiri, MD Daniel P. Petrylak, MD Released: February 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings